Evidence map›Paper›PMID 38729159›Full record

ArticleCell reports. Medicine2024

Intratumoral delivery of the chitin-derived C100 adjuvant promotes robust STING, IFNAR, and CD8

Joanna L Turley, Ross W Ward, Jorge Huete-Carrasco, Natalia Muñoz-Wolf, Kate Roche, Lei Jin, Andrew Bowie, Mats Andersson, Ed C Lavelle

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. T cell-intrinsic PRR signaling in immunity and pathology.Acta biochimica et biophysica Sinica · 2026
    Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Joanna L TurleyAdjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, D02 R590 Dublin 2, Ireland.
Ross W WardAdjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, D02 R590 Dublin 2, Ireland.
Jorge Huete-CarrascoAdjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, D02 R590 Dublin 2, Ireland.
Natalia Muñoz-WolfAdjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, D02 R590 Dublin 2, Ireland.
Kate RocheAdjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, D02 R590 Dublin 2, Ireland.
Lei JinDepartment of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, Gainesville, FL, USA.
Andrew BowieSchool of Biochemistry and Immunology, Trinity Biomedical Science Institute (TBSI), Trinity College Dublin, D02 R590 Dublin, Ireland.
Mats AnderssonDivision Bioscience and Materials, RISE (Research Institutes of Sweden), Forskargatan 18, 151 36 Södertälje, Sweden.
Ed C LavelleAdjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, D02 R590 Dublin 2, Ireland; Centre for Research on Adaptive Nanostructures and Nanodevices (CRANN) & Advanced Materials Bio-Engineering Research Centre (AMBER), Trinity College Dublin, D02 PN40 Dublin 2, Ireland. Electronic address: lavellee@tcd.i.e.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stimulator of IFN genes (STING) is a promising target for adjuvants utilized in in situ cancer vaccination approaches. However, key barriers remain for clinical translation, including low cellular uptake and accessibility, STING variability necessitating personalized STING agonists, and interferon (IFN)-independent signals that can promote tumor growth. Here, we identify C100, a highly deacetylated chitin-derived polymer (HDCP), as an attractive alternative to conventional STING agonists. C100 promotes potent anti-tumor immune responses, outperforming less deacetylated HDCPs, with therapeutic efficacy dependent on STING and IFN alpha/beta receptor (IFNAR) signaling and CD8

Indexed as

Adjuvants, ImmunologicCD8-Positive T-LymphocytesChitinMembrane ProteinsMice, Inbred C57BLReceptor, Interferon alpha-betaSignal TransductionAnimalsCancer VaccinesCell Line, TumorFemaleHumansMiceNeoplasmsNucleotidyltransferasesProgrammed Cell Death 1 ReceptorAdjuvants, ImmunologicCancer VaccinesChitinIfnar1 protein, mouseMembrane ProteinsNucleotidyltransferasesProgrammed Cell Death 1 ReceptorReceptor, Interferon alpha-betaSting1 protein, mouseSTING Proteinadjuvantcancer immunotherapycancer vaccineCD8+ T cellchitin derived polymerchitosanDNA sensinginterferonSTING

Identifiers

PMID38729159
PMCPMC11148802

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.